(-0.41%) 5 460.48 points
(-0.12%) 39 119 points
(-0.71%) 17 733 points
(-0.34%) $81.46
(-3.13%) $2.60
(0.01%) $2 336.90
(0.61%) $29.44
(0.28%) $1 009.00
(-0.06%) $0.933
(0.45%) $10.68
(-0.04%) $0.791
(0.86%) $85.73
0.78% HKD 25.70
Live Chart Being Loaded With Signals
Livzon Pharmaceutical Group Inc. engages in the research, development, production, and sale of pharmaceutical products, and active pharmaceutical ingredients and intermediates in the People's Republic of China...
Stats | |
---|---|
Объем за сегодня | 297 300 |
Средний объем | 674 076 |
Рыночная капитализация | 33.58B |
EPS | HKD0.650 ( Q1 | 2024-03-31 ) |
Дата следующего отчета о доходах | ( HKD0.603 ) 2024-08-22 |
Last Dividend | HKD1.744 ( 2023-07-04 ) |
Next Dividend | HKD0 ( N/A ) |
P/E |
11.22 (Sector) 14.27 (Industry) 0 |
ATR14 | HKD0.0300 (0.12%) |
Объем Корреляция
Livzon Pharmaceutical Корреляция
10 Самые положительные корреляции |
---|
10 Самые отрицательные корреляции |
---|
Вы знали?
Корреляция - это статистический показатель, описывающий связь между двумя переменными. Он изменяется от -1 до 1, где -1 указывает на идеальную отрицательную корреляцию (при увеличении одной переменной другая уменьшается), 1 указывает на идеальную положительную корреляцию (при увеличении одной переменной другая увеличивается), а 0 указывает на отсутствие корреляции (между переменными нет связи).
Корреляцию можно использовать для анализа связи между любыми двумя переменными, не только акциями. Она широко используется в таких областях, как финансы, экономика, психология и т. д.
Livzon Pharmaceutical Корреляция - Валюта/Сырье
Livzon Pharmaceutical Финансовые показатели
Annual | 2023 |
Выручка: | HKD12.43B |
Валовая прибыль: | HKD7.96B (64.08 %) |
EPS: | HKD2.10 |
FY | 2023 |
Выручка: | HKD12.43B |
Валовая прибыль: | HKD7.96B (64.08 %) |
EPS: | HKD2.10 |
FY | 2022 |
Выручка: | HKD12.63B |
Валовая прибыль: | HKD8.17B (64.68 %) |
EPS: | HKD2.04 |
FY | 2021 |
Выручка: | HKD12.06B |
Валовая прибыль: | HKD7.81B (64.75 %) |
EPS: | HKD1.900 |
Financial Reports:
No articles found.
Livzon Pharmaceutical Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD1.744 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
Very Unsafe
High risk of being cut
Unsafe
Heightened risk of being cut
Borderline
Moderate risk of being cut
Safe
Unlikely to be cut
Very Safe
Very unlikely to be cut
First Dividend | HKD0.221 | 2014-07-08 |
Last Dividend | HKD1.744 | 2023-07-04 |
Next Dividend | HKD0 | N/A |
Payout Date | 0000-00-00 | |
Next Payout Date | N/A | |
# dividends | 10 | -- |
Total Paid Out | HKD9.31 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 3 | -- |
Div. Sustainability Score | 9.98 | |
Div.Growth Potential Score | 6.03 | |
Div. Directional Score | 8.01 | -- |
Year | Amount | Yield |
---|
The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. However, its Dividend Growth Potential Score (DGPS) is only moderate, indicating limited growth potential. In summary, the company provides a promising overall dividend outlook, balancing both sustainability and growth potential.
Ex Date | Amount | Declaration Date | Record Date | Payment Date |
---|---|---|---|---|
04 Jul 2023 | HKD1.744 | 30 Nov -0001 | 30 Nov -0001 | 30 Nov -0001 |
30 May 2022 | HKD1.512 | 30 Nov -0001 | 30 Nov -0001 | 30 Nov -0001 |
01 Jun 2021 | HKD1.506 | 30 Nov -0001 | 30 Nov -0001 | 30 Nov -0001 |
04 Jun 2020 | HKD1.253 | 30 Nov -0001 | 30 Nov -0001 | 30 Nov -0001 |
03 Jul 2019 | HKD1.050 | 30 Nov -0001 | 30 Nov -0001 | 30 Nov -0001 |
22 Jun 2018 | HKD1.455 | 30 Nov -0001 | 30 Nov -0001 | 30 Nov -0001 |
05 Jul 2017 | HKD0.260 | 30 Nov -0001 | 30 Nov -0001 | 30 Nov -0001 |
15 Jun 2016 | HKD0.270 | 30 Nov -0001 | 30 Nov -0001 | 30 Nov -0001 |
02 Jul 2015 | HKD0.0444 | 30 Nov -0001 | 30 Nov -0001 | 30 Nov -0001 |
08 Jul 2014 | HKD0.221 | 30 Nov -0001 | 30 Nov -0001 | 30 Nov -0001 |
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
2360.HK | Ex Dividend Knight | 2023-10-03 | Annually | 0 | 0.00% | |
0636.HK | Ex Dividend Knight | 2023-09-07 | Semi-Annually | 0 | 0.00% | |
1857.HK | Ex Dividend Junior | 2023-08-23 | Semi-Annually | 0 | 0.00% | |
0217.HK | Ex Dividend Junior | 2023-07-05 | Sporadic | 0 | 0.00% | |
1286.HK | Ex Dividend Knight | 2023-08-21 | Semi-Annually | 0 | 0.00% | |
3718.HK | Ex Dividend Knight | 2023-09-11 | Semi-Annually | 0 | 0.00% | |
0857.HK | Ex Dividend Knight | 2023-09-12 | Semi-Annually | 0 | 0.00% | |
2111.HK | Ex Dividend Knight | 2023-09-13 | Annually | 0 | 0.00% | |
0393.HK | Ex Dividend Knight | 2023-09-14 | Semi-Annually | 0 | 0.00% | |
1598.HK | Ex Dividend Junior | 2023-07-13 | Annually | 0 | 0.00% |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | 0.161 | 1.500 | 6.77 | 10.00 | [0 - 0.5] |
returnOnAssetsTTM | 0.0786 | 1.200 | 7.38 | 8.86 | [0 - 0.3] |
returnOnEquityTTM | 0.142 | 1.500 | 9.53 | 10.00 | [0.1 - 1] |
payoutRatioTTM | 0.799 | -1.000 | 2.01 | -2.01 | [0 - 1] |
currentRatioTTM | 2.06 | 0.800 | 4.69 | 3.75 | [1 - 3] |
quickRatioTTM | 1.802 | 0.800 | 4.11 | 3.29 | [0.8 - 2.5] |
cashRatioTTM | 1.338 | 1.500 | 3.68 | 5.52 | [0.2 - 2] |
debtRatioTTM | 0.141 | -1.500 | 7.64 | -10.00 | [0 - 0.6] |
interestCoverageTTM | 24.70 | 1.000 | 1.962 | 1.962 | [3 - 30] |
operatingCashFlowPerShareTTM | 4.14 | 2.00 | 8.62 | 10.00 | [0 - 30] |
freeCashFlowPerShareTTM | 3.25 | 2.00 | 8.37 | 10.00 | [0 - 20] |
debtEquityRatioTTM | 0.244 | -1.500 | 9.02 | -10.00 | [0 - 2.5] |
grossProfitMarginTTM | 0.645 | 1.000 | 2.58 | 2.58 | [0.2 - 0.8] |
operatingProfitMarginTTM | 0.206 | 1.000 | 7.88 | 7.88 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | 1.087 | 1.000 | 5.07 | 5.07 | [0.2 - 2] |
assetTurnoverTTM | 0.487 | 0.800 | -0.0887 | -0.0709 | [0.5 - 2] |
Total Score | 9.98 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | 11.29 | 1.000 | 8.96 | 0 | [1 - 100] |
returnOnEquityTTM | 0.142 | 2.50 | 9.70 | 10.00 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | 3.25 | 2.00 | 8.92 | 10.00 | [0 - 30] |
dividendYielPercentageTTM | 7.29 | 1.500 | 10.00 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | 4.14 | 2.00 | 8.62 | 10.00 | [0 - 30] |
payoutRatioTTM | 0.799 | 1.500 | 2.01 | -2.01 | [0 - 1] |
pegRatioTTM | 1.625 | 1.500 | 2.50 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | 0.316 | 1.000 | 4.60 | 0 | [0.1 - 0.5] |
Total Score | 6.03 |
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Livzon Pharmaceutical
Livzon Pharmaceutical Group Inc. engages in the research, development, production, and sale of pharmaceutical products, and active pharmaceutical ingredients and intermediates in the People's Republic of China. The company offers Ilaprazole enteric coated tablets for the treatment of duodenal ulcers and reflux esophagitis; Laprazole sodium for injection to treat peptic ulcer hemorrhage; Leuprorelin Acetate Microspheres for injection; Urofollitropin for injection to treat anovulation and sufferers; Perospirone Hydrochloride for the treatment of schizophrenia; Anti-viral Granules to treat upper respiratory tract infection and influenza; and Shenqi Fuzheng Injection for the treatment of weakness and tiredness, lassitude, spontaneous sweating, and vertigo, as well as for the patients of lung and stomach cancer. It also offers diagnostic reagents, such as diagnostic kit for IgM/IgG antibody to coronavirus; nucleic acid test kit for human immunodeficiency virus type 1; antinuclear antibody test kits; interferon-gamma release assays test kits; and rapid test for mycoplasma pneumoniae IgM antibody. In addition, the company provides biochemical drugs, microbiological preparations, biologic products, Chinese drug preparations and pharmaceutical raw materials, and antibiotics. It also exports its products. The company was founded in 1985 and is headquartered in Zhuhai, China.
О Торговые сигналы
Данные торговые сигналы, представленные на этой странице, помогают определить, когда следует ПОКУПАТЬ или ПРОДАВАТЬ NA. Сигналы имеют задержку более 1 минуты. Пожалуйста, примите во внимание, что существует вероятность ошибки или неточностей в силу различных микро и макро факторов влияющих на фондовые рынки.
Данные тор“о”ые сигна“ы не являются определен“ыми, и getagraph.com не несет ответственности за какие-либо действия, предпринятые в от“ошении этих сигналов, как описано в Terms of Use. Сигналы основаны на широком спектре индикаторов технического анализа